Category: Pharma Industry

News Alert

Total 340B Drug Purchases Reached $66 Billion in 2023

October 18, 2024 William Newton, Associate Editor/Senior Writer Views

Total 340B purchases reached $66.3 billion in 2023, according to new HRSA data released Oct. 18.

Drug purchases under the 340B program reached $66.3 billion in 2023, marking a 24% increase over the $54 billion in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

State Contract Pharmacy Lawsuit Weekly Roundup: New Filings in Missouri, Minnesota

October 18, 2024 William Newton, Associate Editor/Senior Writer & Shannon Young, Associate Editor/Senior Writer Views

Key motions were recently filed in state contract pharmacy litigation in Missouri and Minnesota.

Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

PhRMA Pans Government’s Response to J&J’s 340B Rebate Proposal in Letter to HRSA Administrator

October 16, 2024 William Newton, Associate Editor/Senior Writer Views

PhRMA sent an Oct. 11 letter to HRSA criticizing the agency's opposition to J&J's 340B rebate proposal.

Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Health Leader Slams J&J Rebate Proposal, Urges Providers to ‘Remain Vigilant’ in Op-Ed

October 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

Maureen Testoni, the president and CEO of 340B Health celebrated J&J’s retreat from a 340B rebate proposal in an Oct. 9 RACmonitor op-ed.

The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Providers Raise Caution on Claims Data Submission Requirements After 340B ESP Terms of Use Update Continues to Defer to Manufacturers

October 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.

Editor’s Note: An earlier version of this story incorrectly suggested that an Oct. 4 update to 340B ESP’s terms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Health Centers Urge Federal Appeals Court to Take Their Side in Case Alleging Drug Manufacturer Collusion on Contract Pharmacy Restrictions

October 16, 2024 Bella Czajkowski, National Correspondent Views

Two community health centers argued in a Sept. 30 filing with the U.S. 2nd Circuit Court of Appeals that diabetes drugmakers colluded to place contract pharmacy restrictions.

Two community health centers urged a federal appeals court to overturn the dismissal of their 340B antitrust lawsuit, arguing in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models

October 10, 2024 William Newton, Associate Editor/Senior Writer Views

CMS has not assumed responsibility for “deduplicating” discounts that arise between the 340B program and the IRA's Medicare drug price negotiations.

Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Head of Drug Industry-Funded Think Tank Backs J&J’s Proposed Rebate Model, Slams Hospitals in Op-Ed

October 10, 2024 Shannon Young, Associate Editor/Senior Writer Views

Sally Pipes, the president and CEO of the drug-industry funded Pacific Research Institute, criticized pushback that led Johnson & Johnson to forgo its plans to implement a 340B rebate model in an Oct. 7 Forbes op-ed.

The leader of a right-leaning think tank that’s received funding from the drug industry criticized pushback that led Johnson & [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

CMS’ MDRP Final Rule May Impact 340B Covered Drugs, Attorneys Say

October 8, 2024 William Newton, Associate Editor/Senior Writer Views

CMS' recently-released MDRP final rule may affect 340B covered drugs and draw litigation.

A new federal regulation updating the definition of a covered outpatient drug could change the number of drugs covered under [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

GSK Announces Specialty Pharmacy Senderra No Longer Eligible to Dispense Asthma Drug

October 8, 2024 Bella Czajkowski, National Correspondent Views

Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.

Specialty pharmacy Senderra Rx will no longer dispense GlaxoSmithKline’s (GSK’s) asthma treatment Nucala, the drug manufacturer announced on industry vendor [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live